NEW YORK, Nov. 4 (GenomeWeb News) - Becton Dickinson today reported that total revenues increased 8 percent in the third quarter to $1.3 billion from $1.2 billion year over year.
Sales at BD's Biosciences unit were flat at $89 million.
BD spent $59 million on research and development in the quarter, up 12 percent from $52 million for the same quarter in 2003.
Net income receded to $67 million for the period from $161 million in the year-ago quarter. The decline reflected a $116 million charge relating to BD's plans to sell its Clontech unit.
BD did not disclose its cash position.